Rabies vaccine is under clinical development by AstriVax and currently in Phase I for Rabies. According to GlobalData, Phase I drugs for Rabies have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rabies vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rabies vaccine overview
The vaccine candidate is under development for the prevention of rabies infection. It is a live attenuated vaccine and is being developed based on Plasmid-Launched Live Attenuated Virus (PLLAV) platform.
AstriVax overview
AstriVax is an innovative vaccine platform company that develops prophylactic and therapeutic vaccines. The company’s pipeline products comprise yellow fever vaccine, rabies vaccine and chronic hepatitis B vaccine and therapeutic human papillomavirus (HPV) vaccine. It uses DNA-based technology that launches self-amplifying live attenuated viruses, resulting in polyfunctional and vigorous nature of the immune response to develop the plasmid-launched live attenuated virus (PLLAV) platform. AstriVax is headquartered in Leuven, Flemish Brabant, Belgium.
For a complete picture of Rabies vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
